BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients
Simple Summary
- Supplementary File 1:
ZIP-Document (ZIP, 33 KiB)
Park, J.H.; Jo, J.H.; Jang, S.I.; Chung, M.J.; Park, J.Y.; Bang, S.; Park, S.W.; Song, S.Y.; Lee, H.S.; Cho, J.H. BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients. Cancers 2022, 14, 236. https://doi.org/10.3390/cancers14010236
Park JH, Jo JH, Jang SI, Chung MJ, Park JY, Bang S, Park SW, Song SY, Lee HS, Cho JH. BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients. Cancers. 2022; 14(1):236. https://doi.org/10.3390/cancers14010236
Chicago/Turabian StylePark, Ji H., Jung H. Jo, Sung I. Jang, Moon J. Chung, Jeong Y. Park, Seungmin Bang, Seung W. Park, Si Y. Song, Hee S. Lee, and Jae H. Cho. 2022. "BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients" Cancers 14, no. 1: 236. https://doi.org/10.3390/cancers14010236